Watch Video

Purolite Praesto AP+ Platform, including the high-performance AP+50, is designed to meet the demands of modern biopharmaceutical purification. Built around a proprietary engineered protein A ligand based on the C domain, these resins offer technical equivalence to legacy platforms ensuring seamless integration into existing workflows with minimal disruption.

AP+50 supports advanced process intensification strategies such as multi-column, continuous, and rapid cycling chromatography. Its high dynamic binding capacity at low residence times, shorter bed heights, and robust alkaline stability enable faster throughput, reduced buffer usage, and improved resin utilization. Whether you're optimizing monoclonal antibody purification or scaling up therapeutic production, Purolite’s AP+ platform deliver flexibility, performance, and cost-efficiency backed by full regulatory support.

In this webinar, Principal Scientist Benjamin Summers walks through the performance, flexibility, and cost-efficiency of Praesto™ AP+50 highlighting its plug-and-play compatibility with legacy resins, high dynamic binding capacity, and robust alkaline stability.

''Purolite™ Praesto™ AP+50 is a resin that builds in flexibility so you can design a process and a method of intensification that works for your specific requirements''

Benjamin Summers
Principal Scientist

What makes AP+ resins technically equivalent to legacy resins?

AP+50 use a proprietary engineered protein A ligand based on the C domain, offering high alkaline resistance and structural similarity to legacy resins. This ensures compatibility with existing purification protocols and minimal disruption to downstream workflows.

How does AP+50 perform in terms of dynamic binding capacity (DBC)?

AP+50 consistently shows higher DBC than leading legacy resins across a range of residence times for both polyclonal and monoclonal antibodies. This translates to fewer cycles, lower operator hours, and increased yield per run.

Can AP+50 be used for process intensification?

Yes. AP+50 supports multi-column, continuous, and rapid cycling chromatography. Its high capacity at low residence times and shorter bed heights enables faster throughput, reduced buffer usage, and improved resin utilization.

Are there any tech transfer challenges when switching to AP+50 from competitor resins or previous versions?

From a technical equivalence standpoint, we haven’t seen significant challenges. The only considerations arise when changing bead size, which can affect pressure flow and column dimensions. Regulatory compliance is more relevant when switching ligand identities, but between AP+50 and AP+80, this isn’t an issue - they use the same ligand on different bead technologies.

Is the increased binding capacity primarily due to the change in bead size?

Yes, much of the benefit comes from the smaller bead size, which increases surface area and enhances binding. Additionally, our jetted technology  produces beads that are more uniform-like, improving mass transfer. This leads to faster transitions to plateauing and better performance at lower residence times, even compared to similarly sized resins.  ligand identities, but between AP+50 and AP+80, this isn’t an issue - they use the same ligand on different bead technologies.

Affinity Resin Selection Guide Cover
Unlock the full potential of your downstream purification processes, download our Affinity Resin Selection guide now.

Download Now

Is AP+50 compatible with existing cleaning-in-place (CIP) protocols?

Absolutely. It maintains over 80% of initial DBC after 100 cycles using either 0.1 M or 0.5 M sodium hydroxide, offering flexibility for stringent cleaning requirements without compromising resin integrity.

What is the dual flow strategy and how does it improve productivity?

Dual flow involves loading 80% of the product at a faster residence time and the remaining 20% at a slower rate. This maximizes binding capacity, reduces cycle count, and lowers buffer consumption.

Do you offer validation protocols to support regulatory submissions? 

Yes, Ecolab Life Sciences has a dedicated regulatory team and a comparability transfer outline to help guide customers through necessary experiments and documentation required in this situation. Please contact us for more information on your specific requirements for further information.  

Can you comment on the security of supply if a significant portion of the market shifts to your technology?

Security of supply is a top concern across the bioprocessing industry, with many now pursuing dual-sourcing strategies to mitigate supply risks and ensure uninterrupted operations.  

However, implementing a dual-sourcing resin strategy comes with multiple challenges and we're committed to supporting our customers overcome those. Our team of scientists at our Applications Lab provide hands-on assistance with resin screening, validation, and data generation. We also provide regulatory guidance to help our customers navigate an increasingly complex compliance landscape. 

On the manufacturing side, we are further strengthening our resin security with a major expansion of our UK facility, doubling our capacity. In addition, our patented jetting technology streamlines resin production, helping to shorten lead times for our customers. 

Overall, we are well positioned to meet increased resin demand and support industry growth. 

Bioprocessing Knowledge Hub

Explore our comprehensive resources, which include expert whitepapers on emerging trends, detailed product guides for bioprocessing products, video tutorials demonstrating new techniques, and in-depth ebooks on critical bioprocessing aspects.

Find out more